All In Biotech

Drug Trial Radar · NCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 614 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

614

Planned (sponsor's estimate)

Start

Dec 15, 2023

Primary completion

Jan 25, 2028

Study completion May 27, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Sacituzumab tirumotecanBiological

    IV infusion

  • PembrolizumabBiological

    IV infusion

  • Supportive care measuresDrug

    Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 49 months

Locations

220 sites in 26 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix ( Site 0147)

    Phoenix, Arizona · Recruiting

  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130)

    Burbank, California · Recruiting

  • Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132)

    Grand Junction, Colorado · Recruiting

  • Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)

    Jacksonville, Florida · Recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106)

    Marietta, Georgia · Completed

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0121)

    Louisville, Kentucky · Completed

  • New England Cancer Specialists ( Site 0143)

    Westbrook, Maine · Recruiting

  • University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144)

    Worcester, Massachusetts · Completed

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115)

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic - Rochester ( Site 0148)

    Rochester, Minnesota · Recruiting

  • Hattiesburg Clinic Hematology/Oncology ( Site 0104)

    Hattiesburg, Mississippi · Recruiting

  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134)

    Reno, Nevada · Recruiting

  • University Hospitals Cleveland Medical Center ( Site 0119)

    Cleveland, Ohio · Completed

  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117)

    Corvallis, Oregon · Recruiting

  • Oncology Consultants P.A. ( Site 0129)

    Houston, Texas · Completed

  • Hospital Aleman-Oncology ( Site 0300)

    Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0306)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Británico de Buenos Aires-Oncology ( Site 0304)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)

    Río Cuarto, Córdoba Province, Argentina · Recruiting

  • Instituto de Oncología de Rosario ( Site 0301)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002)

    Port Macquarie, New South Wales, Australia · Recruiting

  • Westmead Hospital ( Site 3000)

    Westmead, New South Wales, Australia · Recruiting

  • Grampians Health-Medical Oncology ( Site 3001)

    Ballarat Central, Victoria, Australia · Completed

  • Northern Hospital ( Site 3003)

    Epping, Victoria, Australia · Recruiting

  • Peninsula University Hospital ( Site 3004)

    Frankston, Victoria, Australia · Recruiting

  • Instituto Nacional de Câncer - INCA ( Site 0405)

    Rio de Janeiro, Brazil · Recruiting

  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0401)

    São Paulo, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0409)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Clinica Viver ( Site 0400)

    Santa Maria, Rio Grande do Sul, Brazil · Active not recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0402)

    Barretos, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0406)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • William Osler Health System ( Site 0203)

    Brampton, Ontario, Canada · Recruiting

  • Trillium Health Partners - Credit Valley Hospital ( Site 0202)

    Mississauga, Ontario, Canada · Recruiting

  • McGill University Health Centre ( Site 0200)

    Montreal, Quebec, Canada · Completed

  • Bradford Hill Norte ( Site 0516)

    Antofagasta, Chile · Recruiting

  • Clinica Universidad Catolica del Maule-Oncology ( Site 0501)

    Talca, Maule Region, Chile · Recruiting

  • Orlandi Oncologia-Oncology ( Site 0504)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • FALP-UIDO ( Site 0509)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill-Clinical Area ( Site 0507)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Second Affiliated hospital of Anhui Medical University ( Site 3133)

    Hefei, Anhui, China · Completed

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.